Fej-nyaki daganatok: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• PD-1 70
• PD-L1 42
• TP53 7
• EGFR 33
• PI3K 6
• STAT3 1
• BRAF 0
• AKT 2
• mTOR 0
• HER2 6
• RET 0
• MAPK 0
• ERK 0
• STING 0
• PTEN 1
• TERT 0
• CTNNB1 0
• JAK 1
• CTLA-4 4
• NRF2 0
• MYC 0
• VEGF 4
• YAP 1
• HIF-1 0
• MET 3
• AMPK 0
• CLDN18 0
• IL-6 2
• JNK 0
• PARP 1
• FGFR 1
• GPX4 0
• B7-H3 5
• CD47 1
• COX-2 0
• LAG-3 2
• TROP2 5
• EZH2 0
• MEK 0
• METTL3 0
• PIK3CA 4
• CDK4/6 2
• NLRP3 0
• ATM 0
• PKM2 0
• TNF 0
• FAK 0
• MMP-9 0
• PPAR 0
• PSMA 1
• TLR4 0
• BCL-2 0
• HSP90 0
• KRAS 0
• NOTCH1 0
• NTRK 1
• ALK 0
• CD40 1
• CDKN2A 2
• CXCR4 0

3+ intézményből 3, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NIDCR · F31

  Investigating the impact of radiation therapy on oral squamous cell carcinoma microenvironment via non-classical class I major histocompatibility complex HLA-E

  University of California at Davis· Davis, Egyesült Államok· 43 748 USD awarded in fiscal year 2026· until 2029. aug.

• NIH NIDCR · F32

  Transposon derived neo-antigens in NSD1 mutant Head and Neck Cancers

  Columbia University Health Sciences· New York, Egyesült Államok· 77 580 USD awarded in fiscal year 2026· until 2028. szept.

• NIH NIAID · R56

  Functional dissection of a novel E2 complex critical for the HPV16 life cycle

  Virginia Commonwealth University· Richmond, Egyesült Államok· 768 308 USD awarded in fiscal year 2026· until 2027. aug.

• NIH NIDCR · R01

  Restoring responses to immunotherapy in metastatic lymph nodes in HNSCC

  University of California, San Francisco· San Francisco, Egyesült Államok· 684 832 USD awarded in fiscal year 2026· until 2031. júl.

• NIH NIDCR · R01

  Advancing FTIR-based Multimodal Imaging with AI for Risk Stratification of Oral Precancer

  University of Missouri Kansas City· Kansas City, Egyesült Államok· 527 533 USD awarded in fiscal year 2026· until 2030. jún.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Epigenetic Profiling and Telomere-Orchestrated Mechanisms in HPV+ Oropharyngeal Cancer (EPiTOME-M)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 268 569 EUR· until 2028. nov.· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Endoscopic tissue time machine (EPIC)

  King's College London· London, Egyesült Királyság· EU contribution 2 273 033 EUR· until 2031. máj.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  From Whisper to Voice: Real-Time on-Device Assistive AI Technology for Human Connection (Whispp)

  Whispp Bv· Leiden, Hollandia· EU contribution 2 498 319 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  INHIBITING RESISTANCE TO IMMUNOTHERAPY IN HEAD&NECK CANCER BY TARGETING NETRIN-1 (NeckNET)

  Netris Pharma Sas· Lyon, Franciaország· EU contribution 7 248 398 EUR· until 2030. máj.· 4 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  Early clinical development of first-in-class EGL-001 targeting Tregs in head and neck squamous cell carcinoma, supported by AI-based pathomics (NEOTREG)

  Egle Therapeutics· Suresnes, Franciaország· EU contribution 7 999 120 EUR· until 2028. nov.· 4 countries

10 of 560 running projects, newest first. Listed amounts together: 324,0 M USD + 36,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

  NCT04681469· Gruppo Oncologico del Nord-Ovest· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 84
• Organoids 23
• Mendelian Randomization Analysis 49
• CRISPR-Cas Systems 13
• Gene Expression Profiling 244
• Sequence Analysis, RNA 26
• Whole Genome Sequencing 7
• Exome Sequencing 22
• Proteomics 65
• Metabolomics 43
• Mass Spectrometry 14
• Flow Cytometry 56
• Immunohistochemistry 333
• Liquid Biopsy 34
• Circulating Tumor DNA 57
• Xenograft Model Antitumor Assays 308
• Positron-Emission Tomography 83
• Magnetic Resonance Imaging 276
• Machine Learning 232
• Deep Learning 187
• Cohort Studies 296
• Genome-Wide Association Study 55

• CRISPR-based point-of-care platform for EBV DNA screening and monitoring in nasopharyngeal cancer plasma.

  Talanta, 2026. szept.

• CRISPR-Engineered CAR-T Cell Therapy for Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma: A Review of Emerging Therapeutic Prospects.

  Rev Med Virol, 2026. szept.

• CRISPR-Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer.

  Mol Carcinog, 2026. ápr.

• CRISPR-cas9-Mediated Gene Editing to Reverse Oncogenic Mutations in Oral Squamous Cell Carcinoma.

  Ann Afr Med, 2026. márc.

• Genome-wide CRISPR Screening Reveals a PKA-Driven Resistance Mechanism to Metformin for Oral Cancer Prevention That Can Be Exploited by Combination with NSAIDs.

  Cancer Prev Res (Phila), 2026. febr.

• Single-Nucleotide Variation Analysis in Oral Squamous Cell Carcinoma-Related ctDNA by dCas9/sgRNA Recognition-Mediated Proximity Ligation-Triggered Terminal Hairpin Formation and Self-Priming Amplification.

  Anal Chem, 2026. jan.

• SULF1 in Cancer Associated Fibroblasts Promotes Invasion in Head and Neck Cancer Cell Lines.

  Cancer Med, 2026. jan.

• Targeted demethylation of the BRD7 promoter based on CRISPR/dCas9 system inhibits the malignant progression of nasopharyngeal carcinoma.

  Clin Transl Med, 2026. jan.

• Single-Step CRISPR/Cas13a Assay for detection of small RNAs in Saliva : a proof-of-concept study.

  Cancer Genet, 2025. dec.

• H3K36 Methylation as a Guardian of Epigenome Integrity.

  Nat Commun, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.